Answers are grounded in this paper and cite their sources.
Compares chemosensory alterations in COVID-19 and AERD, suggesting unique diagnostic profiles.
BACKGROUND: Persistent chemosensory dysfunction (CSD) occurs in both COVID-19 and aspirin-exacerbated respiratory disease (AERD). The similarities and differences in chemosensory experiences of these two conditions remain undefined and poorly understood. OBJECTIVE: To compare qualitative and quantitative chemosensory alterations and quality of life impact in individuals with COVID-19-associated versus AERD-associated CSD. METHODS: Participants from the Brigham and Women's Hospital (BWH) COVID-19 CSD registry (n=406) and BWH AERD registry (n=389) completed online questionnaires assessing CSD characteristics, sinonasal disease-related quality of life. RESULTS: COVID-19 CSD showed a distinct qualitative phenotype. Sixty percent of COVID-19 participants reported that odors smelled different than they recalled versus 19% with AERD (p<0.001). Unpleasant odor perception was experienced by over 20% of COVID-19 participants but by less than 5% of AERD participants. COVID-19 CSD involved selective impairment and unpleasant distortion of sour, bitter, and umami, whereas AERD showed a uniform quantitative reduction across taste modalities. Flavor distortions, particularly for foods with bitter or fatty components (e.g., coffee, chocolate, nut butter) and chemesthetic flavors (e.g., spicy, mint, alcohol, garlic, ginger), were significantly more common in COVID-19 CSD (average: 25%) than in AERD (average: 0%). Both conditions were associated with impaired QoL, including odor and food safety-related concerns. CONCLUSION: Both COVID-19 CSD and AERD cause profound chemosensory disruption. However, COVID-19 CSD is distinguished by marked qualitative distortions in smell, taste, flavor, and chemesthesis. In contrast, AERD CSD reflects more generalized sensory reduction. Incorporating these characteristic sensory profiles into routine evaluation may improve diagnostic accuracy and guide patient counseling for ongoing chemosensory care.
No takes yet. Share an insight, caveat, or question.
Minichetti et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: